Anti-body Coupled T Receptor Therapy Market

Anti-body Coupled T Receptor Therapy Market Global Industry Insights, Trends, Outlook and
Opportunity Analysis 2018-2026
Anti-body coupled T receptor (ACTR) therapy is kind of immunotherapy used to treat cancer in
which body’s own immune response is utilized to act on cancerous cell. Anti-body coupled T
receptor therapy utilizes T cells from body, engineered it to express specific T cell receptor,
multiplying it in lab and then administering it along with targeting antibodies. The advantage
in this approach is, that these T cells do not attack normal antigens from blood circulation but
attack only antigens attached to the cancerous cells. This is possible as tumor specific
monoclonal antibodies are given together with ACTR T cells. ACTR therapy is cost effective as
it can be used in various cancer therapy. Also, greater therapeutic benefit with minimum side
effects can be possible by adjusting the amount of targeting antibody which is essential for
activation of the ACTR T cells.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1600
Rising incidence of cancer and new products to be launched in future to drive the market for
anti-body coupled T receptor therapy market.
According to World Health Organization (WHO), cancer is one of the leading non-communicable
disease and second leading cause of death globally. As reported by International Agency for
Research on Cancer (IARC) in 2012, there were 14.1 million new cases, 8.8 million deaths and
32.6 million people living with cancer worldwide. As per 2017 report by Leukemia and
Lymphoma Society, U.S. alone is expected to have prevalence of 8,16,834 and 80,500 annual
new cases of lymphoma. Therefore, such high number of cancer patient would propel the antibody coupled T receptor therapy market.
ACTR therapy is better in its approach than other adoptive T cell transfer technologies such as
CAR-T cell therapy. CAR-T therapy products such as Kymriah (Novartis AG) or Yescarta (Gilead
Lifescience, Inc.) has side effects such as cytokine release syndrome, and neurological toxicity as
discussed in their respective product literatures and other studies. ACTR therapy being specific
in its action do not produce such side effects. This advantage would drive the anti-body
coupled T receptor therapy market in future. Also CAR-T therapy has application in specific
type of cancer such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple
myeloma whereas ACTR therapy has potential use even in solid tumorous cancer such as breast
cancer, and neuroblastoma.
Cost of product can be a major concern. Kymriah which is a CAR-T therapy costs
approximately US$ 4,75,000 per patient. Considering such high cost for CAR-T therapy it can
be assumed that anti-body coupled T receptor therapy can also costs on similar line as it works
in same segment of immuno oncology, which may limit the potential growth of anti-body
coupled T receptor therapy market.
Report includes chapters which deeply display the following deliverable about industry :
• Anti-body Coupled T Receptor Therapy Market Research Objective and Assumption
• Anti-body Coupled T Receptor Therapy Market Purview - Report Description, Executive
Summary, and Coherent Opportunity Map (COM)
• Anti-body Coupled T Receptor Therapy Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Anti-body Coupled T Receptor Therapy Market, By Regions
• Anti-body Coupled T Receptor Therapy Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
• Anti-body Coupled T Receptor Therapy Market Manufacturers Profiles/Analysis including
Company Basic Information, Manufacturing Base and Its Competitors.
• Anti-body Coupled T Receptor Therapy Market Manufacturing Cost Analysis including Key
Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Anti-body Coupled T Receptor Therapy Market Forecast including Production, Consumption,
Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Ask For Discount Before Purchasing This Business Report @
https://www.coherentmarketinsights.com/insight/request-discount/1600
Strategic merger and acquisition amongst the companies to expand the market for anti-body
coupled T receptor therapy.
Unum Therapeutics is currently the only company that is working actively in anti-body coupled
T receptor therapy. It has several product in its pipeline, and they vary based on the
technology used for expression of receptor in patients T cell such as mRNA or viral vector.
There is also combination of different monoclonal antibodies to be used for coupling such as
rituximab, and trastuzumab. In phase one clinical trial, rituximab coupled t receptor therapy
found to produce desired therapeutic effects. Seattle Genetics, Inc. and Unum Therapeutics, Inc.
in 2015 entered into a strategic collaboration and license agreement to develop and
commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer. This
collaboration would enable study of different combination of the tumor-specific monoclonal
antibodies with T receptor and cater to patient specific treatment needs.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Anti-body coupled T receptor (ACTR) therapy is kind of immunotherapy used to treat cancer in which body’s own immune response is utilized to act on cancerous cell.